• It's your time to find the health care job that fits you!
  • It's your choice to choose a health care recruiting firm with your interests in mind!
  • It's your turn to find a career in health care that is right for you!
  • It's your move, make it a good one!
  • It's YOUR health care career!
OB/GYN News

Rapid HIV Tests Highly Effective In Preventing Mother-to-Child HIV Transmission In India, Study Finds

Fri, 09 May 2008 12:00:00 PDT
Rapid HIV tests have been found to be highly effective in preventing mother-to-child HIV transmission in clinical trials in India, according to a study published online Tuesday in PLoS Medicine, the Times of India reports (Sinha, Times of India, 5/7). For the study, the researchers used

Denver Post Examines Outlook For Embryonic Stem Cell Research Policy Shift With Next President
Fri, 09 May 2008 06:00:00 PDT
The Denver Post on Wednesday examined possible changes to federal funding for human embryonic stem cell research with the next president. According to the Post, stem cell research in the U.S. is "likely to get a fresh look" from the next president, "no matter who it is.

'Telepsychiatry' Allows Nurses To Treat Women With Postpartum Depression
Fri, 09 May 2008 05:00:00 PDT
Women suffering with postpartum depression may in future be able to receive psychotherapy from a specially trained nurse over the phone, eliminating barriers to treatment such as distance, time or the availability of a psychologist or psychiatrist.Professor Cindy-Lee Dennis, Canada Research Chair in Perinatal Community Health at U of T's Lawrence S.

Opponents Of Colo. Ballot Proposal Warn Against Unintended Consequences For Physicians, Women
Fri, 09 May 2008 05:00:00 PDT
A coalition of opponents against a Colorado ballot initiative that would define a fertilized embryo as a person and extend to it rights and protections under the state constitution said Tuesday that the amendment could lead to a range of unintended consequences for women and doctors in the state, the AP/Denver Post reports.

BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer
Fri, 09 May 2008 00:00:00 PDT
BiPar Sciences, Inc. announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on going trials in breast and brain cancer.


 



SEARCHING FOR A JOB!
Contact us by filling out the simple form below to get started.